TScan Therapeutics
TCRX
TScan Therapeutics (TCRX) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.28
- EPS estimate
- −$0.33
- EPS surprise
- +14.40%
- Revenue surprise
- +135.71%
- Revenue
- $3.1M
- Revenue estimate
- $1.3M
- Reported
- Aug 12, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 12, 2025 | −$0.33 | −$0.28 | +14.40% | $3.1M | SEC |
| Q1 2025 | May 6, 2025 | −$0.29 | −$0.26 | +10.87% | $2.2M | SEC |
| Q4 2024 | Mar 5, 2025 | −$0.32 | −$0.30 | +5.90% | $665,000.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.32 | −$0.25 | +20.74% | $1.0M | SEC |
| Q2 2024 | Aug 12, 2024 | −$0.28 | −$0.28 | +1.03% | $536,000.00 | SEC |
| Q1 2024 | May 13, 2024 | −$0.26 | −$0.32 | −23.46% | $600,000.00 | SEC |
| Q4 2023 | Mar 6, 2024 | −$0.29 | −$0.21 | +27.39% | $7.2M | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.45 | −$0.24 | +46.97% | $3.9M | SEC |
| Q2 2023 | Aug 10, 2023 | −$0.77 | −$0.51 | +33.33% | $3.1M | SEC |
| Q1 2023 | May 10, 2023 | −$0.69 | −$0.93 | −34.30% | $6.8M | SEC |
| Q4 2022 | Mar 8, 2023 | −$0.72 | −$0.78 | −7.73% | $3.1M | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.73 | −$0.67 | +7.71% | $3.4M | SEC |
| Q2 2022 | Aug 10, 2022 | −$0.74 | −$0.63 | +15.32% | $4.1M | SEC |
| Q1 2022 | May 9, 2022 | −$0.70 | −$0.67 | +4.29% | $3.0M | SEC |
| Q4 2021 | Mar 9, 2022 | −$0.70 | −$0.60 | +14.29% | $2.9M | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.61 | −$0.80 | −32.23% | $2.4M | SEC |
| Q2 2021 | Aug 19, 2021 | −$0.65 | −$7.69 | −1092.25% | $2.8M | SEC |
Quarterly revenue
Frequently asked questions
When did TScan Therapeutics (TCRX) last report earnings?
TScan Therapeutics last reported on Aug 12, 2025, covering fiscal Q2 2025.
Did TCRX beat earnings estimates?
Yes. TScan Therapeutics reported EPS of −$0.28 for Q2 2025 against a −$0.33 estimate — a 14.40% beat.
How much revenue did TCRX report last quarter?
TScan Therapeutics reported $3.1M in revenue for Q2 2025, against a consensus estimate of $1.3M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.